Jump to section

IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomy# Sabarubicin

This drug entry is a

**stub**and has not been fully annotated. It is scheduled to be annotated soon.## Identification

- Name
- Sabarubicin
- Accession Number
- DB12410
- Type
- Small Molecule
- Groups
- Investigational
- Description
Sabarubicin has been used in trials studying the treatment of Prostate Cancer, Testicular Germ Cell Tumor, and Unspecified Adult Solid Tumor, Protocol Specific.

- Structure
- Synonyms
- Not Available
- External IDs
- MEN-10755
- Categories
- UNII
- XS499WOZ93
- CAS number
- 211100-13-9
- Weight
- Average: 643.6351

Monoisotopic: 643.226490275 - Chemical Formula
- C
_{32}H_{37}NO_{13} - InChI Key
- VQHRZZISQVWPLK-UIRGBLDSSA-N
- InChI
- InChI=1S/C32H37NO13/c1-12-26(37)17(33)7-21(43-12)46-31-13(2)44-22(8-18(31)35)45-19-10-32(42,20(36)11-34)9-16-23(19)30(41)25-24(29(16)40)27(38)14-5-3-4-6-15(14)28(25)39/h3-6,12-13,17-19,21-22,26,31,34-35,37,40-42H,7-11,33H2,1-2H3/t12-,13-,17-,18-,19-,21-,22-,26+,31+,32-/m0/s1
- IUPAC Name
- (7S,9S)-7-{[(2R,4S,5S,6S)-5-{[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-5,7,8,9,10,12-hexahydrotetracene-5,12-dione
- SMILES
- [H][[email protected]]1(N)C[[email protected]]([H])(O[[email protected]]2([H])[[email protected]]([H])(C)O[[email protected]]([H])(C[[email protected]]2([H])O)O[[email protected]@]2([H])C[[email protected]@](O)(CC3=C(O)C4=C(C(O)=C23)C(=O)C2=CC=CC=C2C4=O)C(=O)CO)O[[email protected]@]([H])(C)[[email protected]@]1([H])O

## Pharmacology

- Indication
- Not Available
- Structured Indications
- Not Available
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available

## Interactions

- Drug Interactions
Drug Interaction Drug group Aceclofenac Aceclofenac may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Investigational Acemetacin Acemetacin may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Experimental, Investigational Acetyldigitoxin The serum concentration of Acetyldigitoxin can be decreased when it is combined with Sabarubicin. Approved Acetyldigoxin The serum concentration of Acetyldigoxin can be decreased when it is combined with Sabarubicin. Experimental Acetylsalicylic acid Acetylsalicylic acid may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Vet Approved Adapalene Adapalene may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved Alclofenac Alclofenac may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Withdrawn Alcuronium Sabarubicin may increase the respiratory depressant activities of Alcuronium. Experimental Alendronic acid Sabarubicin may increase the hypocalcemic activities of Alendronic acid. Approved Alminoprofen Alminoprofen may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Experimental Amdinocillin The serum concentration of Sabarubicin can be decreased when it is combined with Amdinocillin. Investigational, Withdrawn Amoxicillin The serum concentration of Sabarubicin can be decreased when it is combined with Amoxicillin. Approved, Vet Approved Amphotericin B Amphotericin B may increase the nephrotoxic activities of Sabarubicin. Approved, Investigational Ampicillin The serum concentration of Sabarubicin can be decreased when it is combined with Ampicillin. Approved, Vet Approved Andrographolide Andrographolide may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Investigational Anisodamine Anisodamine may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Investigational Antipyrine Antipyrine may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved Apocynin Apocynin may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Investigational Apremilast Apremilast may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Investigational Aspoxicillin The serum concentration of Sabarubicin can be decreased when it is combined with Aspoxicillin. Experimental Atracurium Sabarubicin may increase the respiratory depressant activities of Atracurium. Experimental, Investigational Atracurium besylate Sabarubicin may increase the respiratory depressant activities of Atracurium besylate. Approved Azapropazone Azapropazone may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Withdrawn Azelastine Azelastine may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved Azidocillin The serum concentration of Sabarubicin can be decreased when it is combined with Azidocillin. Approved Azlocillin The serum concentration of Sabarubicin can be decreased when it is combined with Azlocillin. Approved Bacampicillin The serum concentration of Sabarubicin can be decreased when it is combined with Bacampicillin. Approved, Investigational Balsalazide Balsalazide may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Investigational Bendazac Bendazac may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Experimental Benorilate Benorilate may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Experimental Benoxaprofen Benoxaprofen may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Withdrawn Benzathine benzylpenicillin The serum concentration of Sabarubicin can be decreased when it is combined with Benzathine benzylpenicillin. Approved, Vet Approved Benzydamine Benzydamine may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved Benzylpenicillin The serum concentration of Sabarubicin can be decreased when it is combined with Benzylpenicillin. Approved, Vet Approved Benzylpenicilloyl Polylysine The serum concentration of Sabarubicin can be decreased when it is combined with Benzylpenicilloyl Polylysine. Approved Bevonium Bevonium may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Experimental Botulinum Toxin Type A Sabarubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A. Approved, Investigational Botulinum Toxin Type B Sabarubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B. Approved Bromfenac Bromfenac may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved Bucillamine Bucillamine may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Investigational Bufexamac Bufexamac may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Experimental Bumadizone Bumadizone may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Experimental Bumetanide The risk or severity of adverse effects can be increased when Bumetanide is combined with Sabarubicin. Approved Capreomycin Capreomycin may increase the neuromuscular blocking activities of Sabarubicin. Approved Carbenicillin The serum concentration of Sabarubicin can be decreased when it is combined with Carbenicillin. Approved, Investigational Carbenicillin indanyl The serum concentration of Sabarubicin can be decreased when it is combined with Carbenicillin indanyl. Approved, Investigational Carboplatin Sabarubicin may increase the ototoxic activities of Carboplatin. Approved Carfecillin The serum concentration of Sabarubicin can be decreased when it is combined with Carfecillin. Experimental Carprofen Carprofen may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Vet Approved, Withdrawn Castanospermine Castanospermine may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Experimental Celecoxib Celecoxib may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Investigational Chloroquine Chloroquine may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Vet Approved Choline magnesium trisalicylate Choline magnesium trisalicylate may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved Cisatracurium Sabarubicin may increase the respiratory depressant activities of Cisatracurium. Approved, Experimental Cisatracurium besylate Sabarubicin may increase the respiratory depressant activities of Cisatracurium besylate. Approved Cisplatin Cisplatin may increase the nephrotoxic activities of Sabarubicin. Approved Clodronic Acid Sabarubicin may increase the hypocalcemic activities of Clodronic Acid. Approved, Investigational, Vet Approved Clonixin Clonixin may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved Cloxacillin The serum concentration of Sabarubicin can be decreased when it is combined with Cloxacillin. Approved, Vet Approved Colistimethate Sabarubicin may increase the nephrotoxic activities of Colistimethate. Approved, Vet Approved Curcumin Curcumin may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Investigational Cyclacillin The serum concentration of Sabarubicin can be decreased when it is combined with Cyclacillin. Approved Cyclosporine Sabarubicin may increase the nephrotoxic activities of Cyclosporine. Approved, Investigational, Vet Approved Cymarin The serum concentration of Cymarin can be decreased when it is combined with Sabarubicin. Experimental D-Limonene D-Limonene may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Investigational Decamethonium Sabarubicin may increase the respiratory depressant activities of Decamethonium. Approved Deslanoside The serum concentration of Deslanoside can be decreased when it is combined with Sabarubicin. Approved Diclofenac Diclofenac may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Vet Approved Dicloxacillin The serum concentration of Sabarubicin can be decreased when it is combined with Dicloxacillin. Approved, Vet Approved Difenpiramide Difenpiramide may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Experimental Diflunisal Diflunisal may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved Digitoxin The serum concentration of Digitoxin can be decreased when it is combined with Sabarubicin. Approved, Investigational Digoxin The serum concentration of Digoxin can be decreased when it is combined with Sabarubicin. Approved Digoxin Immune Fab (Ovine) The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Sabarubicin. Approved Domoic Acid Sabarubicin may increase the respiratory depressant activities of Domoic Acid. Experimental Doxacurium chloride Sabarubicin may increase the respiratory depressant activities of Doxacurium chloride. Approved Droxicam Droxicam may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved Duvelisib Duvelisib may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Investigational E-6201 E-6201 may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Investigational Epicillin The serum concentration of Sabarubicin can be decreased when it is combined with Epicillin. Experimental Epirizole Epirizole may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved Etacrynic acid The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Sabarubicin. Approved Etanercept Etanercept may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Investigational Ethenzamide Ethenzamide may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Experimental Etidronic acid Sabarubicin may increase the hypocalcemic activities of Etidronic acid. Approved Etodolac Etodolac may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Investigational, Vet Approved Etofenamate Etofenamate may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Investigational Etoricoxib Etoricoxib may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Investigational Evening primrose oil Evening primrose oil may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Investigational exisulind exisulind may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Investigational Felbinac Felbinac may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Experimental Fenbufen Fenbufen may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved Fenoprofen Fenoprofen may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved Fentiazac Fentiazac may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Experimental Feprazone Feprazone may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Experimental Ferulic acid Ferulic acid may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Experimental Floctafenine Floctafenine may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Withdrawn Flucloxacillin The serum concentration of Sabarubicin can be decreased when it is combined with Flucloxacillin. Approved, Investigational Flunixin Flunixin may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Vet Approved Flunoxaprofen Flunoxaprofen may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Experimental Flurbiprofen Flurbiprofen may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Investigational Foscarnet Foscarnet may increase the nephrotoxic activities of Sabarubicin. Approved Furosemide The risk or severity of adverse effects can be increased when Furosemide is combined with Sabarubicin. Approved, Vet Approved Gallamine Sabarubicin may increase the respiratory depressant activities of Gallamine. Experimental Gallamine Triethiodide Sabarubicin may increase the respiratory depressant activities of Gallamine Triethiodide. Approved Gitoformate The serum concentration of Gitoformate can be decreased when it is combined with Sabarubicin. Experimental Guacetisal Guacetisal may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Experimental Higenamine Higenamine may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Investigational Ibandronate Sabarubicin may increase the hypocalcemic activities of Ibandronate. Approved, Investigational Ibuprofen Ibuprofen may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved Ibuproxam Ibuproxam may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Withdrawn Icatibant Icatibant may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved Imidazole salicylate Imidazole salicylate may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Experimental Indobufen Indobufen may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Investigational Indomethacin Indomethacin may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Investigational Indoprofen Indoprofen may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Withdrawn Isoxicam Isoxicam may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Withdrawn Kebuzone Kebuzone may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Experimental Ketoprofen Ketoprofen may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Vet Approved Ketorolac Ketorolac may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved Lanatoside C The serum concentration of Lanatoside C can be decreased when it is combined with Sabarubicin. Experimental Leflunomide Leflunomide may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Investigational Lisofylline Lisofylline may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Investigational Lonazolac Lonazolac may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Experimental Lornoxicam Lornoxicam may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Investigational Loxoprofen Loxoprofen may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Investigational Lumiracoxib Lumiracoxib may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Investigational Magnesium salicylate Magnesium salicylate may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved Mannitol Mannitol may increase the nephrotoxic activities of Sabarubicin. Approved, Investigational Masoprocol Masoprocol may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Investigational Mecamylamine Sabarubicin may increase the neuromuscular blocking activities of Mecamylamine. Approved Meclofenamic acid Meclofenamic acid may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Vet Approved Mefenamic acid Mefenamic acid may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved Meloxicam Meloxicam may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Vet Approved Mesalazine Mesalazine may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved Metamizole Metamizole may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Investigational, Withdrawn Metampicillin The serum concentration of Sabarubicin can be decreased when it is combined with Metampicillin. Experimental Meticillin The serum concentration of Sabarubicin can be decreased when it is combined with Meticillin. Approved, Investigational Metildigoxin The serum concentration of Metildigoxin can be decreased when it is combined with Sabarubicin. Experimental Metocurine Sabarubicin may increase the respiratory depressant activities of Metocurine. Approved Metocurine Iodide Sabarubicin may increase the respiratory depressant activities of Metocurine Iodide. Withdrawn Mezlocillin The serum concentration of Sabarubicin can be decreased when it is combined with Mezlocillin. Approved, Investigational Mivacurium Sabarubicin may increase the respiratory depressant activities of Mivacurium. Approved Mizoribine Mizoribine may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Investigational Mofebutazone Mofebutazone may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Experimental Mycophenolate mofetil Mycophenolate mofetil may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Investigational Mycophenolic acid Mycophenolic acid may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved Nabumetone Nabumetone may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved Nafamostat Nafamostat may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Investigational Nafcillin The serum concentration of Sabarubicin can be decreased when it is combined with Nafcillin. Approved Naftifine Naftifine may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved Naproxen Naproxen may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Vet Approved Neosaxitoxin Sabarubicin may increase the respiratory depressant activities of Neosaxitoxin. Investigational Nepafenac Nepafenac may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved Nifenazone Nifenazone may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Experimental Niflumic Acid Niflumic Acid may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved Nimesulide Nimesulide may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Investigational, Withdrawn Nitroaspirin Nitroaspirin may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Investigational Oleandrin The serum concentration of Oleandrin can be decreased when it is combined with Sabarubicin. Experimental, Investigational Olopatadine Olopatadine may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved Olsalazine Olsalazine may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved Orgotein Orgotein may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Vet Approved Ouabain The serum concentration of Ouabain can be decreased when it is combined with Sabarubicin. Approved Oxacillin The serum concentration of Sabarubicin can be decreased when it is combined with Oxacillin. Approved Oxaprozin Oxaprozin may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved Oxyphenbutazone Oxyphenbutazone may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Withdrawn Pamidronate Sabarubicin may increase the hypocalcemic activities of Pamidronate. Approved Pancuronium Sabarubicin may increase the respiratory depressant activities of Pancuronium. Approved Parecoxib Parecoxib may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved Parthenolide Parthenolide may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Investigational Penamecillin The serum concentration of Sabarubicin can be decreased when it is combined with Penamecillin. Experimental Penimepicycline The serum concentration of Sabarubicin can be decreased when it is combined with Penimepicycline. Experimental Peruvoside The serum concentration of Peruvoside can be decreased when it is combined with Sabarubicin. Experimental Phenoxymethylpenicillin The serum concentration of Sabarubicin can be decreased when it is combined with Phenoxymethylpenicillin. Approved, Vet Approved Phenylbutazone Phenylbutazone may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Vet Approved Pimecrolimus Pimecrolimus may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Investigational Pipecuronium Sabarubicin may increase the respiratory depressant activities of Pipecuronium. Approved Piperacillin The serum concentration of Sabarubicin can be decreased when it is combined with Piperacillin. Approved Piretanide The risk or severity of adverse effects can be increased when Piretanide is combined with Sabarubicin. Experimental Pirfenidone Pirfenidone may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Investigational Piroxicam Piroxicam may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Investigational Pirprofen Pirprofen may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Experimental Pivampicillin The serum concentration of Sabarubicin can be decreased when it is combined with Pivampicillin. Approved Pivmecillinam The serum concentration of Sabarubicin can be decreased when it is combined with Pivmecillinam. Approved Pranoprofen Pranoprofen may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Experimental, Investigational Procaine benzylpenicillin The serum concentration of Sabarubicin can be decreased when it is combined with Procaine benzylpenicillin. Approved, Vet Approved Proglumetacin Proglumetacin may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Experimental Propacetamol Propacetamol may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Investigational Propicillin The serum concentration of Sabarubicin can be decreased when it is combined with Propicillin. Experimental Propyphenazone Propyphenazone may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Experimental Proquazone Proquazone may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Experimental Proscillaridin The serum concentration of Proscillaridin can be decreased when it is combined with Sabarubicin. Experimental PTC299 PTC299 may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Investigational Pyrantel Sabarubicin may increase the respiratory depressant activities of Pyrantel. Approved, Vet Approved Rapacuronium Sabarubicin may increase the respiratory depressant activities of Rapacuronium. Withdrawn Resveratrol Resveratrol may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Experimental, Investigational Risedronate Sabarubicin may increase the hypocalcemic activities of Risedronate. Approved, Investigational Rocuronium Sabarubicin may increase the respiratory depressant activities of Rocuronium. Approved Rofecoxib Rofecoxib may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Investigational, Withdrawn Salicylamide Salicylamide may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved Salicylic acid Salicylic acid may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Vet Approved Salsalate Salsalate may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved Semapimod Semapimod may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Investigational Seratrodast Seratrodast may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved Serrapeptase Serrapeptase may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Investigational SRT501 SRT501 may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Investigational Succinylcholine Sabarubicin may increase the respiratory depressant activities of Succinylcholine. Approved Sulbactam The serum concentration of Sabarubicin can be decreased when it is combined with Sulbactam. Approved Sulbenicillin The serum concentration of Sabarubicin can be decreased when it is combined with Sulbenicillin. Experimental Sulfasalazine Sulfasalazine may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved Sulindac Sulindac may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved Sultamicillin The serum concentration of Sabarubicin can be decreased when it is combined with Sultamicillin. Investigational Suprofen Suprofen may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Withdrawn Suxibuzone Suxibuzone may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Experimental Talampicillin The serum concentration of Sabarubicin can be decreased when it is combined with Talampicillin. Experimental Tarenflurbil Tarenflurbil may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Investigational Tazobactam The serum concentration of Sabarubicin can be decreased when it is combined with Tazobactam. Approved Technetium Tc-99m etidronate Sabarubicin may increase the hypocalcemic activities of Technetium Tc-99m etidronate. Approved Technetium Tc-99m medronate Sabarubicin may increase the hypocalcemic activities of Technetium Tc-99m medronate. Approved Tenidap Tenidap may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Experimental Tenofovir disoproxil The serum concentration of Sabarubicin can be increased when it is combined with Tenofovir disoproxil. Approved, Investigational Tenoxicam Tenoxicam may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved Tepoxalin Tepoxalin may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Vet Approved Teriflunomide Teriflunomide may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved Tiaprofenic acid Tiaprofenic acid may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved Ticarcillin The serum concentration of Sabarubicin can be decreased when it is combined with Ticarcillin. Approved, Investigational, Vet Approved Tiludronic acid Sabarubicin may increase the hypocalcemic activities of Tiludronic acid. Approved, Investigational, Vet Approved Tinoridine Tinoridine may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Investigational Tolfenamic Acid Tolfenamic Acid may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved Tolmetin Tolmetin may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved Torasemide The risk or severity of adverse effects can be increased when Torasemide is combined with Sabarubicin. Approved Tranilast Tranilast may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Investigational Tribenoside Tribenoside may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Experimental Triptolide Triptolide may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Investigational Tubocurarine Sabarubicin may increase the respiratory depressant activities of Tubocurarine. Approved Valdecoxib Valdecoxib may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Investigational, Withdrawn Vancomycin Vancomycin may increase the nephrotoxic activities of Sabarubicin. Approved Vecuronium Sabarubicin may increase the respiratory depressant activities of Vecuronium. Approved Zaltoprofen Zaltoprofen may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Investigational Zileuton Zileuton may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Approved, Investigational, Withdrawn Zoledronic acid Sabarubicin may increase the hypocalcemic activities of Zoledronic acid. Approved Zomepirac Zomepirac may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Withdrawn - Food Interactions
- Not Available

## References

- General References
- Not Available
- External Links
- PDB Entries
- 1nab

## Clinical Trials

- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Treatment Testicular germ cell tumour / Unspecified Adult Solid Tumor, Protocol Specific 1 1 Completed Treatment Unspecified Adult Solid Tumor, Protocol Specific 1 2 Completed Treatment Prostate Cancer 1

## Pharmacoeconomics

- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available

## Properties

- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 1.25 mg/mL ALOGPS logP 1.14 ALOGPS logP 1.04 ChemAxon logS -2.7 ALOGPS pKa (Strongest Acidic) 9.1 ChemAxon pKa (Strongest Basic) 11.05 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 14 ChemAxon Hydrogen Donor Count 7 ChemAxon Polar Surface Area 235.53 Å ^{2}ChemAxon Rotatable Bond Count 6 ChemAxon Refractivity 157.49 m ^{3}·mol^{-1}ChemAxon Polarizability 65.71 Å ^{3}ChemAxon Number of Rings 6 ChemAxon Bioavailability 0 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET features
- Not Available

## Spectra

- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available

## Taxonomy

- Description
- This compound belongs to the class of organic compounds known as anthracyclines. These are polyketides containing a tetracenequinone ring structure with a sugar attached by glycosidic linkage.
- Kingdom
- Organic compounds
- Super Class
- Phenylpropanoids and polyketides
- Class
- Anthracyclines
- Sub Class
- Not Available
- Direct Parent
- Anthracyclines
- Alternative Parents
- Tetracenequinones / Aminoglycosides / Anthraquinones / O-glycosyl compounds / Disaccharides / Tetralins / Aryl ketones / Oxanes / Vinylogous acids / Tertiary alcohols show 12 more
- Substituents
- Anthracycline / Anthracyclinone-skeleton / Aminoglycoside core / Tetracenequinone / 9,10-anthraquinone / 1,4-anthraquinone / Anthracene / Disaccharide / Glycosyl compound / O-glycosyl compound show 30 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available

Drug created on October 20, 2016 16:16 / Updated on December 01, 2017 16:30